Entity

Time filter

Source Type


Litvinenko G.I.,Research Institute of Physiology and Fundamental Medicine | Shurlygina A.V.,Research Institute of Physiology and Fundamental Medicine | Dergacheva T.I.,Research Institute of Clinical and Experimental Lymphology | Mel'Nikova E.V.,Research Institute of Physiology and Fundamental Medicine | Trufakin V.A.,Research Institute of Physiology and Fundamental Medicine
Bulletin of Experimental Biology and Medicine | Year: 2015

We compared the effectiveness of immunomodulators used in the treatment of patients with chronic salpingitis and oophoritis with or without changes in succinate dehydrogenase (SDH) activity in blood lymphocytes at incubation with the drug. Diurnal variations in individual reaction of SDH in blood lymphocytes to thymalin or ridostin were revealed. In the groups of women receiving ridostin or thymalin during the reaction of lymphocyte SDH to it, improvement of clinical laboratory and immunological parameters was observed in the majority of the patients and no effect was found in a lesser group of patients than in the groups treated with drugs during the absence of lymphocyte SDH reaction thereto. The timing of the presence of SDH reaction to drugs in the immunocompetent cells makes it possible to set the optimal daily regime of their application and to select a drug that would be most effective in each particular case. © 2015 Springer Science+Business Media New York. Source


Shevchenko A.V.,Research Institute of Clinical and Experimental Lymphology | Konenkov V.I.,Research Institute of Clinical and Experimental Lymphology | Garbukov E.Yu.,Research Institute of Oncology | Stakheeva M.N.,Research Institute of Oncology
Voprosy Onkologii | Year: 2014

There were analyzed associating of functional polymorphism of the promoter regions of genes MMP2 C-1306T, MMP 9 C-1562 T, MMP3 5A-1171 6A in a group of healthy women and breast cancer patients in order to identify informative markers associated with the risk of developing the disease. The study included 395 DNA samples from women with breast cancer and 329 healthy women. Genotyping of polymorphisms was carried out by restriction analysis of amplification products (RFLP-analysis). Among female patients there was revealed significantly seldom a carrier of 6A6A MMP3-1117 and MMP 9-1562TT genotypes and also significantly increased the frequency of MMP3 5A6A genotype. The risk of lymph node metastasis reduced in patients with MMP9-1562CC genotype. Conversely heterozygosis at this position could be regarded as risk factor for metastasis. It was revealed associating of MMP3 5A6A genotype with the degree of malignancy. Source


Klimontov V.V.,Research Institute of Clinical and Experimental Lymphology | Myakina N.E.,Research Institute of Clinical and Experimental Lymphology
Diabetes Mellitus | Year: 2014

Glargine became the first long-acting insulin analogue. Glargine was designed to meet basal insulin requirements throughout the day with a single injection. Pharmacokinetics of insulin glargine is characterized by biotransformation into metabolites M1 and M2 that transforms the B chain of glargine so it is similar to the B chain of human insulin. Plasma concentrations of active M1 and M2 metabolites have no pronounced peaks during the day, resulting in lower glucose variability and hypoglycaemia risk when compared with NPH insulin. The metabolic activities of M1 and M2 metabolites are similar to the effect of glargine, whereas the mitogenic effects of these metabolites do not exceed the effect of human insulin. Insulin glargine shows a higher affinity for the insulin-like growth factor-1 (IGF-1) receptor when compared with human insulin. Glargine has no proliferative effect in vivo owing to its rapid conversion into metabolites. Pharmacokinetic and pharmacodynamic variability of glargine is comparable to other insulins. These characteristics are important for the clinical efficacy and safety of glargine. Source


Konenkov V.I.,Research Institute of Clinical and Experimental Lymphology | Klimontov V.V.,Research Institute of Clinical and Experimental Lymphology
Diabetes Mellitus | Year: 2014

Genetic and cellular techniques emerge as promising modalities for the treatment of diabetic foot syndrome. Two patient groups potentially to benefit most from these novel methods are patients with critical lower limb ischemia (CLLI) in whom angiosurgery is not indicated, and patients with trophic ulcers resistant to conventional therapy. A series of clinical trials has shown positive effects of transferring VEGF, HIF-1, FGF, PDGF, HGF and certain other growth factor genes to stimulate blood vessel formation and healing of diabetic ulcers. Autologous transplantation of mononuclear bone marrow and peripheral blood cells, endothelial progenitor cells, mesenchymal stem cells and stromal cell of the adipose tissue has also demonstrated its clinical potential in patients with diabetes mellitus and CLLI. Randomized clinical trials report beneficial effects of gene and cell therapy on such surrogate endpoints as ischemic index, rest pain and ulcer healing, though data on amputation rates is controversial. Further studies are necessary to determine optimal dosage and route of administration of biological agents and predictors of their efficacy, as well as long-term safety of these novel treatment modalities. Source


Robinson M.V.,Research Institute of Clinical and Experimental Lymphology | Mel'nikova E.V.,Research Institute of Clinical and Experimental Lymphology | Trufakin V.A.,Research Institute of Clinical and Experimental Lymphology
Bulletin of experimental biology and medicine | Year: 2015

We found the peculiarities of the effects of dipeptidyl peptidase IV inhibitor diprotin A on immunological parameters of lymphocytes in lymphoid organs in intact animals and in animals with experimental autoimmune process. In intact animals, diprotin A increased cellularity of the thymus and spleen, number of CD4+, CD8+, and CD4+8+ thymocytes and CD3+ splenocytes and reduced cellularity of lymph nodes and the number of antibody-forming cells in the spleen. Diprotin A administered against the background of autoimmune process, reduced thymus cellularity, number of antibody-forming cells in the spleen, and number of CD4 and CD4+8+ thymocytes in comparison with the corresponding parameters of autoimmune process. Source

Discover hidden collaborations